louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04520763: Effects of Respiratory Muscle Exercises on Glucose Tolerance in Healthy Adults
Official title: Effects of Respiratory Muscle Exercises on Glucose Tolerance in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Aging
Healthy Diet
Lead sponsor: Swiss Federal Institute of Technology
Sponsor class: OTHER
First posted: 2020-08-20
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: This study consists of four visits to the laboratory, each separated by at least 24 hours and each lasting approximately 2.5h. Total duration for each participant is approximately 2 weeks. The study is conducted in 40 healthy adults (≥ 18 years). The study is a randomized, controlled cross-over trial. We chose a cross-over design in order to test the effects of different respiratory exercises compared to a control intervention in order to minimize variability since each subject serves as his/her own control. Due to the nature of the intervention (respiratory muscle exercises), it is not possible to blind participants to the interventions.
Primary purpose: OTHER

Brief summary: To evaluate the acute effects of respiratory muscle exercises vs. a control intervention on blood glucose kinetics in healthy adults after an oral glucose tolerance test.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Healthy
* Non-smoking
* Body mass index (BMI): 18.5 - 29.9 kg∙m-2
* Normal lung function
* Willing to adhere to study rules

Exclusion Criteria:

* Known or suspected non-compliance, drug or alcohol abuse
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
* Previous enrolment into the current study
* Intake of medications affecting metabolism, the cardiovascular or the respiratory system, or sleep
* Acute illness or chronic conditions of the gastrointestinal tract, and health conditions affecting metabolism, the cardiovascular or the respiratory system, or sleep
* Pregnancy, breastfeeding, or intention to become pregnant during the study

Primary outcomes:
measure: Peak blood glucose concentration
timeFrame: throughout the study, an expected average of 2 weeks per participant
measure: area under the glucose-time curve
timeFrame: throughout the study, an expected average of 2 weeks per participant
Secondary outcomes:
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich
state: ZH
Study officials:
affiliation: Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich
name: Christin M. Spengler, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04531163: Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
Official title: Possible Ameliorating Effect of N- Acetylcysteine on Type-II Diabetes Induced Nephropathy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Diabetic Kidney Disease
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Keywords: N-Acetyl cysteine
Lipoprotein a
Triglycerides
Total cholesterol
Glycated Haemoglobin
Fasting blood sugar
Serum creatinine
Blood urea nitrogen
Urine analysis
High density lipoprotein
Low density lipoprotein
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2020-08-28
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two arms are being used parallel to each other at the same time. Participants are assigned to two groups in parallel for the duration of the study. One arm is interventional assigned to drug administration and the other is a control arm.
Primary purpose: TREATMENT

Brief summary: The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients.

Study design: Prospective clinical based study. The aim of this work is to study the effect of N-acetylcysteine (NAC) on proteinuria and on the serum level of lipoprotein a (LPa) in diabetes induced nephropathy in type-2 diabetic patients.

Detailed description: This study will be carried on 60 participants with Type 2 Diabetes with age over 20 years.

Participants will be classified into two groups:

1. Group I (Interventional): treated with (NAC) dose of 1200 mg/day for two months in conjunction with conventional treatment.
2. Group II (Non-interventional): control group receive conventional treatment.

All patients will undergo the following:

1. Full medical history will be taken.
2. Laboratory investigations as follows:

Blood samples will be collected for analysis after overnight fasting at the beginning and after 2 months of the study for determination of:

1. Total cholesterol (T-chol).
2. Plasma triglycerides (TG).
3. High density lipoprotein cholesterol (HDL-C).
4. Low density lipoprotein cholesterol (LDL-C).
5. Fasting blood sugar.
6. Blood urea nitrogen (BUN).
7. Serum creatinine (SCr).
8. Urine analysis.
9. Glycated hemoglobin (HbA1c).
10. Lipoprotein (a). In addition, blood pressure will be measured for 24 hr.

Eligibility criteria: Inclusion Criteria:

1. Confirmed diagnosis of Diabetes Mellitus.
2. Age over 20 years.
3. Patients with proteinuria ≥ 30 mg /dl.

Exclusion Criteria:

1. Patients on lipid lowering medications.
2. Cigarette smokers.
3. Presence of liver and heart diseases.

Primary outcomes:
measure: Lipoprotein (a)
timeFrame: 2 months
measure: Triglycerides
timeFrame: 2 months
measure: Systolic blood pressure
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al Azhar University
Study officials:
affiliation: Al-Azhar University
name: Huda M. Salem, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT05861063: The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser
Official title: The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Acne Atrophica
Keywords: Acne Scar, Dezocine, Pain Relief, Fractional CO2 Laser
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2023-05-16
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser


Eligibility criteria: Inclusion Criteria:

1. Age: 18-60 years old, regardless of gender;
2. Clinical diagnosis of atrophic acne scars;
3. Planning to undergo ultra-pulsed CO2 lattice laser therapy;
4. The patient agrees to participate in this experiment and signs an informed consent form

Exclusion Criteria:

1. Those who take sedative drugs for a long time;
2. Patients with sleep apnea syndrome, previous history of hypertension, and blood pressure greater than 160/100mmHg
3. People with severe heart and lung diseases, liver and kidney diseases, psychosis, pregnancy, and communication disorders;
4. Persons who are known to be allergic to the main drug or any of the excipients in Dezocine injection;
5. Increased intracranial pressure or head injury;
6. Acute and chronic alcoholism;
7. People with hypotension, hypothyroidism, acute episodes of asthma, and epilepsy

   -

Primary outcomes:
measure: Visual Analog Score for Pain
timeFrame: 24 hours
measure: Hemodynamic parameters
timeFrame: 24 hours
measure: Heart rate (HR)
timeFrame: 24 hours
measure: oxygen saturation (SpO2)
timeFrame: 24 hours
Secondary outcomes:
measure: Occurrence of Adverse Reactions
timeFrame: 24 hours
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Dermatology Derpartment of Xijing Hospital
state: Shaanxi
Study officials:
affiliation: Dermatology Derpartment of Xijing Hospital
name: Gang Wang, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01613963: Causes of Visual Loss in Retinal Disease
Official title: Observational Study of Visual Outcomes in Retinal Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Uveitis
Scleritis
Keywords: Uveitis
Scleritis
Lead sponsor: Royal Surrey County Hospital NHS Foundation Trust
Sponsor class: OTHER
First posted: 2012-06-07
Enrollment: 2000
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with ocular inflammation

Brief summary: This is a study of visual outcomes in retinal disease that seeks to identify the causes of visual loss. This data will be used to predict which patients are at risk of losing vision and how they can be better treated.

Detailed description: This is a study of visual outcomes in retinal disease. It is an observational study of patients who have been seen in the retinal clinic, and involves a retrospective casenotes analysis to identify patients who have suffered visual loss and the reason for that visual loss. These data will be analysed to enable the identification of factors that predict visual loss in patients who present earlier in the course of their disease.

Eligibility criteria: Inclusion Criteria:

* patients with a diagnosis of ocular inflammation
* patients with at least 6 months of follow-up

Exclusion Criteria:

* patients without a diagnosis of ocular inflammation
* patients with less than 6 months of follow-up

Primary outcomes:
measure: Visual acuity at 5 years
timeFrame: 5 years
Secondary outcomes:
measure: Visual acuity at 10 years
timeFrame: 10 years
measure: Source of referral
timeFrame: Baseline
measure: Laterality
timeFrame: Baseline
measure: Anatomical diagnosis
timeFrame: Baseline
measure: Aetiological diagnosis
timeFrame: Baseline
measure: Associated systemic disease
timeFrame: Baseline
measure: Complications of disease and causes of visual loss at 5 years
timeFrame: 5 years
measure: Complications of disease and causes of visual loss at 10 years
timeFrame: 10 years
measure: Complications of disease and causes of visual loss
timeFrame: Up to 10 years
measure: Treatment measures employed
timeFrame: Up to 10 years
measure: Complications of disease and treatment
timeFrame: Up to 10 years
measure: Surgical procedures
timeFrame: Up to 10 years
measure: Burden of disease - appointments
timeFrame: Up to 10 years
measure: Burden of disease - outpatient procedures
timeFrame: Up to 10 years
measure: Burden of disease - inpatient procedures
timeFrame: Up to 10 years
measure: Blind registration
timeFrame: Up to 10 years
Other outcomes:
Locations:
city: Guildford
country: United Kingdom
facility: Royal Surrey County Hospital
state: UK
city: London
country: United Kingdom
facility: Moorfields Eye Hospital
Study officials:
affiliation: Royal Surrey County Hospital NHS Foundation Trust
name: Simon RJ Taylor, PhD FRCOphth
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02650063: A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -
Official title: A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Male Adults
Lead sponsor: Santen Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-01-08
Enrollment: 14
Sex: MALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purposes of this study are to evaluate the safety and plasma pharmacokinetics of DE-117 ophthalmic solution (one drop once daily for 7 days) in healthy male adults.


Eligibility criteria: Inclusion Criteria:

* Healthy male adult volunteers

Exclusion Criteria:

* Subjects with any history of severe diseases that preclude participation in this study for safety reasons
* Subjects with any diseases that preclude participation in this study for safety reasons

Primary outcomes:
measure: Area under concentration-time curve (AUC)
timeFrame: 7 days
measure: Maximum plasma concentration (Cmax)
timeFrame: 7 days
measure: Time to maximum plasma concentration (Tmax)
timeFrame: 7 days
measure: Elimination half-life (T1/2)
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Kagoshima
country: Japan
facility: CPC Clinical Trial Hospital, Medipolis Medical Research Institute
Study officials:
References:
Clinical trial NCT00904163: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
Official title: Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epidermolysis Bullosa Dystrophica
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2009-05-19
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults (18 years of age or older) with RDEB diagnosis by a local dermatologist, who can travel to Stanford University Medical Center.

Brief summary: Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional characteristics of patients who survive to adulthood.


Eligibility criteria: Inclusion Criteria:1. Clinical diagnosis of RDEB by local dermatologist. 2. 18 years of age or more and willing to give consent. Exclusion Criteria:1. Medical instability limiting ability to travel to Stanford University Medical Center.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Alfred T Lane
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00671463: Pancreatic Stent to Prevent Leak After Distal Pancreatectomy
Official title: Leak Elimination After Pancreatic Stenting, a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Pancreatic Surgery
Pancreatic Duct Stenting
Pancreatic Cancer
Distal Pancreatectomy
Pancreatic Diseases
Pancreatic Cyst
Pancreatic Ducts
Keywords: Pancreas surgery
Pancreatic adenocarcinoma
Pancreatic neuroendocrine tumor
Pancreatic duct stenting
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: American Society for Gastrointestinal Endoscopy
First posted: 2008-05-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to investigate an intervention to prevent complications after pancreas surgery. The goal is to determine if placing a stent into the pancreatic duct before surgery will decrease or prevent leaking from the pancreatic duct after surgery. Leaks are common after pancreas surgery and can result in serious problems and post-operative pain. The study will compare two groups. One group will have the stent before surgery, and the other group will have standard pancreas surgery, no endoscopy, and no stent.


Eligibility criteria: Inclusion Criteria:

* Adult patients (greater than or equal to 18 years of age)
* Scheduled to undergo an elective laparoscopic or open distal pancreatectomy
* Willing to undergo pre-operative endoscopy
* Consenting to the procedure

Exclusion Criteria:

* Contraindication to abdominal surgery
* Contraindication to general anesthesia or distal pancreatectomy
* Contraindication to upper endoscopy or ERCP
* Prior history of gastric bypass or other abdominal surgery in whom the ampulla will not be accessible via routine ERCP
* Ongoing pancreatitis
* Pancreatic necrosis or abscess
* History of sphincter of Oddi dysfunction
* History of ERCP-induced pancreatitis

Primary outcomes:
measure: Pancreatic leak
timeFrame: Post-operative day 3
Secondary outcomes:
measure: Peritoneal fluid analysis
timeFrame: Daily
measure: Serum biochemical analysis
timeFrame: Daily
measure: Clinical outcomes
timeFrame: Daily
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: MGH
name: Field F Willingham, MD, MPH
role: STUDY_DIRECTOR
affiliation: MGH
name: Denise W Gee, MD
role: STUDY_DIRECTOR
affiliation: MGH
name: Sevdenur Cizginer, MD
role: STUDY_DIRECTOR
affiliation: MGH
name: David W Rattner, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: MGH
name: William R Brugge, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01260363: Comparison of Infiltration Analgesia With Femoral Nerve Block After Hamstrings Anterior Cruciate Ligament Reconstruction
Official title: Pain Treatment After Anterior Cruciate Ligament Reconstruction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Injury of Anterior Cruciate Ligament
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2010-12-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Pain treatment after anterior cruciate ligament reconstruction - Comparison of infiltration analgesia with femoral nerve block after.

Detailed description: Inclusion Criteria:

* Patients undergoing primary anetrior cruciate ligament reconstruction with semiTendinos/gracillis graft
* Age \> 18 year

Exclusion Criteria:

* Revision ACL reconstruction
* Patients with cartilige lision
* Patients with arthritis
* Pregnant women.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing primary anetrior cruciate ligament reconstruction with semiTendinos/gracillis graft
* Age \> 18 year

Exclusion Criteria:

* Revision ACL reconstruction
* Patients with cartilige lision
* Patients with arthritis
* Pregnant women.

Primary outcomes:
measure: Numeric Rang Scale pain
timeFrame: 1 day after operation
Secondary outcomes:
measure: use of analgetics
timeFrame: 0h, 3h, 24h, 48h
Other outcomes:
Locations:
city: Horsens
country: Denmark
facility: Regional Hospital Horsens
Study officials:
affiliation: Regional hospital Horsens, Denmark
name: Theis Thillemann, MD, Ph.d.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kristensen PK, Pfeiffer-Jensen M, Storm JO, Thillemann TM. Local infiltration analgesia is comparable to femoral nerve block after anterior cruciate ligament reconstruction with hamstring tendon graft: a randomised controlled trial. Knee Surg Sports Traumatol Arthrosc. 2014 Feb;22(2):317-23. doi: 10.1007/s00167-013-2399-x. Epub 2013 Jan 23.
Clinical trial NCT06247163: PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
Official title: Prospective PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Small Cell Lung Carcinoma
Lead sponsor: University Hospital, Essen
Sponsor class: OTHER
First posted: 2024-02-07
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with confirmed diagnosis of small cell lung cancer

Brief summary: There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF

Detailed description: The main objective of this study is to determine whether patients with SCLC who have a metabolically active residual tumor in the fluorodeoxyglucose (FDG) PET/CT scan after two to three cycles of induction chemotherapy have a similarly low local recurrence rate with higher dose. There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF. Allocation to PET boost, if confirmed vital tumor rest by PET CT and biopsy.

Eligibility criteria: Inclusion Criteria:

* Histopathologic confirmation
* Limited disease

Exclusion Criteria:

* Other histology than small cell lung cancer
* Further tumor diagnosis
* ECOG 3 or worse
* Extensive disease
* stage IV

Primary outcomes:
measure: Local recurrence free survival
timeFrame: 2 months to 5 years
measure: Distant recurrence free survival
timeFrame: 2 months to 5 years
measure: Overall survival
timeFrame: 2 months to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Essen
country: Germany
facility: University Hospital Essen
Study officials:
References:
Clinical trial NCT01806363: Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone
Official title: A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interactions and Safety Between Telmisartan and Chlorthalidone in Healthy Male Volunteers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension
Keywords: Pharmacokinetics
Safety
Male
Lead sponsor: HanAll BioPharma Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2013-03-07
Enrollment: 60
Sex: MALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical trial to evaluate the pharmacokinetic interactions and safety between telmisartan and chlorthalidone.


Eligibility criteria: Inclusion Criteria:

1. Healthy male subjects
2. Age(yr)between 20 and 50
3. Signed written informed consent

Exclusion Criteria:

1. Known hypersensitivity to investigator product, thiazide, sulphonamide and other drugs or additive.
2. History of any siginificant Sickness, Cardiovascular, Respiratory, Renal, Endocrine, Neurological, Psychic, Cancer, Gasstrointestinal, Hematologic.
3. History of drug and/or alcohol abuse
4. Over 10 tobaccos a day
5. Other condition which in the opinion of the investigator preclude enrollment into the study

Primary outcomes:
measure: Part A : AUC, Cmax of Telmisartan
timeFrame: Over a 24-hour sampling period
measure: Part B : AUC, Cmax of Chlorthalidone
timeFrame: Over a 24-hour sampling period
Secondary outcomes:
measure: Part A : Cmin, tmax, CL/F of Telmisartan
timeFrame: Over a 24-hour sampling period
measure: Part B : Cmin, tmax, CL/F of Chlorthalidone
timeFrame: Over a 24-hour sampling period
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: Kyungpook national university hospital Clionical center
state: Gyeongsangbuk-do
Study officials:
affiliation: KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL, CLINICAL TRIAL CENTER
name: Young Ran Yoon, Associate Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Seong SJ, Lim MS, Lee J, Ohk B, Gwon MR, Kim BK, Kim HJ, Yang DH, Lee HW, Kang WY, Yoon YR. Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects. Clin Drug Investig. 2016 Aug;36(8):613-23. doi: 10.1007/s40261-016-0406-y.